As a significant sign of prognosis, biochemical recurrence (BCR), defined as the return of prostate‐specific antigen (PSA), occurs in 27%‐53% of patients after radical prostatectomy and radiotherapy,4 and tends to happen months or years ahead of other clinical symptoms of PCa recurrence 5 and increases the risk of developing distant metastases, PCa‐specific, and overall mortality.6 Here, KLK3 is linked to posterior cortical atrophy.